Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Comparative Clinical Pathology
Published in: Comparative Clinical Pathology 5/2018

01-09-2018 | Original Article

Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases

Authors: Fayza A. Rahamtalla, Mohammed S. M. Abdalla, Salma B. M. Mudawi, Mohammed A. H. Kheir Elsid, Iman M. Shammat

Published in: Comparative Clinical Pathology | Issue 5/2018

Login to get access

Abstract

Telomerase enzyme activity is considered a widespread and relatively selective tumor cell marker feature that can be used for detecting the presence of various neoplastic cells. The positive activity of telomerase enzyme was also recorded in chronic liver disease and is evaluated as a more appropriate biomarker for differentiating hepatocellular carcinoma (HCC) from chronic liver diseases. The current study aimed to evaluate telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases. The study enrolled 113 patients: HCC (n = 33), cirrhosis (n = 33), and chronic hepatitis (n = 47), jointly with 50 healthy controls. Enzyme-linked immunosorbent assay (ELISA) technique was used to estimate the telomerase, AFP, and AFP-L3 levels in blood samples. The telomerase level was elevated in 70% of HCC patients, and it was significantly higher in HCC patients compared to that in healthy controls (1.38 versus 0.35 ng/ml, respectively; P < 0.01). Serum alpha-fetoprotein (AFP) and Lens culinaris agglutinin-reactive (AFP-L3) levels were also significantly elevated in HCC patients compared to healthy controls (130.76 versus 5.59 ng/ml; P < 0.01) and (59.76 versus 0.49 ng/ml; P < 0.01), respectively. The combination between telomerase and AFP or AFPL-3 lead to increased telomerase sensitivity (85 and 79%, respectively).Telomerase was found to be further sensitive in patients with a tumor size of less than 5 cm as well as to tumors of more than 5 cm. Two healthy control samples showed an increase in telomerase level. The combined use of telomerase, AFP, and AFP-L3 levels might be useful for achieving better sensitivity for HCC patients.
Literature
Abdel Hady A, El Shanawany F, Hassan MM, Anas A, Mostafa I, Abdel Hadi A (2010) Evaluation of human telomerase activity as a novel tumor marker for hepatocellular carcinoma. Life Sci J 7(4):153–161
American Federation for Aging Research (AFAR) (2011) Info-aging Guide to Telomeres and Telomerase. New York, Biol Aging 1–7
Belair CD, Yeager TR, Lopez PM, Reznikoff CA (1997) Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc Natl Acad Sci U S A 94(25):13677–11368CrossRefPubMedPubMedCentral
Bosch FX, Ribes J, Cléries R, Díaz M (2005) Epidemiology of hepatocellular carcinoma. Clin Liver Dis 9(2):191–211CrossRefPubMed
Bruix J, Sherman M (2011) American Association for the Study of Liver Diseases: management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022CrossRefPubMedPubMedCentral
Choi JY, Jung SW, Kim HY, Kim M, Kim Y, Kim DG, Oh EJ (2013) Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AF. World J Gastroenterol 19(3):339–346CrossRefPubMedPubMedCentral
El-Garem H, Khayyal AA, Mosa TE, Ramadan A (2010) Telomerase activity in hepatocellular carcinoma and chronic hepatitis C virus. J Genet Eng Biotechnol 8(1):81–87
Emad IA, Samir MA, Emad EFI, Mohamad TM, Taher IES (2002) Assaying telomerase activity in three different malignant condition in Egyptian patients employing the polymerase chain reaction technique. J Egypt Nat Cancer Inst 14(3):229–236
Episkopou H, Draskovic I, Van Beneden A, Tilman G, Mattiussi M, Gobin M et al (2014) Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. Nucleic Acids Res 42(7):4391–4405CrossRefPubMedPubMedCentral
Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M, Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F (2006) Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 101(3):524–532CrossRefPubMed
Hassan EG, Hanan AH, Ahmed F, Wafaa AA, Mohey EA, Mona S et al (2013) Tissue biomarkers in the early detection of hepatocellular carcinoma among Egyptian patients with chronic hepatitis C: a possible genetic profile. Br J Med Med Res 3(4):1858–1870CrossRef
Heaphy CM, Subhawong AP, Hong SM, Goggins MG, Montgomery EA, Gabrielson E, Netto GJ, Epstein JI, Lotan TL, Westra WH, Shih IM, Iacobuzio-Donahue CA, Maitra A, Li QK, Eberhart CG, Taube JM, Rakheja D, Kurman RJ, Wu TC, Roden RB, Argani P, de Marzo AM, Terracciano L, Torbenson M, Meeker AK (2011) Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes. Am J Pathol 179(4):1608–1615CrossRefPubMedPubMedCentral
Huang FC, Chang CC, Lou PJ, Kuo IC, Chien CW, Chen CT, Shieh FY, Chang TC, Lin JJ (2008) G-quadruplex stabilizer 3,6-bis (1-methyl-4-vinylpyridinium) carbazolediiodide induces accelerated senescence and inhibits tumorigenic properties in cancer cells. Mol Cancer Res 6(6):955–964CrossRefPubMed
Huang YK, Fan XG, Qiu F, Wang ZM (2013) Combined detection of mRNA expression of alpha-fetoprotein in peripheral blood and telomerase activity of monocytes in hepatocellular carcinoma patients. Hepato-Gastroenterology 60(121):1–5PubMed
Ibrahim FF, Sayed MM, El-garem HA, Ghannam MM (2008) Blood telomerase activity and DNA dielectric properties in human hepatocellular carcinoma and chronic liver disease. Biotechnology 7(1):66–72CrossRef
Ishikawa F (1997) Telomere crisis, the driving force in cancer cell evolution. BiochemBiophys Res Commun 230(1):1–6CrossRef
Jakupciak JP, Wang W, Barker PE, Srivastava S, Atha DH (2004) Analytical validation of telomerase activity for cancer early detection. J Mol Diagn 6(3):157–165CrossRefPubMedPubMedCentral
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S (2014) The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomark Prev 23(1):144–153CrossRef
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266(5193):2011–2015CrossRefPubMed
Kobayashi S, Tomokuni A, Takahashi H, Akita H, Sugimura K, Miyoshi N, Moon JH, Yasui M, Omori T, Ohue M, Fujiwara Y, Yano M, Sakon M (2016) The clinical significance of alpha-fetoprotein mRNAs in patients with hepatocellular carcinoma. Gastrointest Tumors 3:141–152CrossRef
Kojima H, Yokosuka O, Imazeki F, Saisho H, Omata M (1997) Telomerase activity and telomere length in hepatocellular carcinoma and chronic liver disease. Gastroenterology 112(2):493–500CrossRefPubMed
Lechel A, Manns MP, Rudolph KL (2004) Telomeres and telomerase: new targets for the treatment of liver cirrhosis and hepatocellular carcinoma. J Hepatol 41(3):491–497CrossRefPubMed
Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):20–37CrossRef
Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M (2010) Serum markers of hepatocellular carcinoma. Dig Dis Sci 55(10):2744–2755CrossRefPubMed
Marrero JA, Feng Z, Wang Y, Nguyen MH, Befeler AS, Roberts LR, Reddy KR, Harnois D, Llovet JM, Normolle D, Dalhgren J, Chia D, Lok AS, Wagner PD, Srivastava S, Schwartz M (2009) Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology 137(1):110–118CrossRefPubMedPubMedCentral
Miura N, Maruyama S, Oyama K, Horie Y, Kohno M, Noma E, Sakaguchi S, Nagashima M, Kudo M, Kishimoto Y, Kawasaki H, Hasegawa J, Shiota G (2007) Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 72(1):45–51CrossRefPubMed
Molenaar C, Wiesmeijer K, Verwoerd N, Khazen S, Eils R, Tanke H, Dirks RW (2003) Visualizing telomere dynamics in living mammalian cells using PNA probes. EMBO J 22(24):6631–6641CrossRefPubMedPubMedCentral
Murnane JP, Sabatier L (2004) Chromosome rearrangements resulting from telomere dysfunction and their role in cancer. BioEssays 26(11):1164–1174CrossRefPubMed
Nouso K, Urabe Y, Higashi T, Nakatsukasa H, Hino N, Ashida K, Kinugasa N, Yoshida K, Uematsu S, Tsuji T (1996) Telomerase as a tool for the differential diagnosis of human hepatocellular carcinoma. Cancer 78(2):232–236CrossRefPubMed
Omer R, Van’t Veer P, Kadaru AM, Kampman E, El Khidir IM, Fedail SS et al (2001) The role of hepatitis B and hepatitis C viral infections in the incidence of hepatocellular carcinoma in Sudan. Trans R Soc Trop Med Hyg 95(5):487–491CrossRefPubMed
Ozen M, Imam SA, Datar RH, Multani AS, Narayanan R, Chung LW et al (1998) Telomeric DNA: marker for human prostate cancer development? Prostate 36(4):264–271CrossRefPubMed
Park YM, Choi JY, Byun BH, Cho CH, Kim HS, Kim BS (1998) Telomerase is strongly activated in hepatocellular carcinoma but not in chronic hepatitis and cirrhosis. Exp Mol Med 30(1):35–40CrossRefPubMed
Pathak S, Risin S, Brown N, Berry K (1994) Telomeric association of chromosomes is an early manifestation of programmed cell-death.Int. J Oncol 4(2):323–328
Satra M, Gatselis N, Iliopoulos D, Zacharoulis D, Dalekos GN, Tsezou A (2007) Real-time quantification of human telomerase reverse transcriptase mRNA in liver tissues from patients with hepatocellular cancer and chronic viral hepatitis (2007). J Viral Hepat 14(1):41–47CrossRefPubMed
Shata YM, Mudawi S, Fedail SS, Al Abd BH, Ismaeil AM, Ahmed SM (2014) Assessment of Lens culinaris agglutinin-reactive fraction of alpha fetoprotein as an early diagnostic marker for hepatocellular carcinoma among Sudanese patients with chronic liver disease. Cancer Oncol Res 2(1):1–6
Stefaniuk P, Cianciara J, Wiercinska-Drapalo A (2010) Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 16(4):418–424CrossRefPubMedPubMedCentral
Tahara H, Nakanishi T, Kitamoto M, Nakashio R, Shay JW, Tahara E, Kajiyama G, Ide T (1995) Telomerase activity in human liver tissues: comparison between chronic liver disease and hepatocellular carcinomas. Cancer Res 55(13):2734–2736PubMed
Tateishi R, Haruhiko Y, Yutaka M, Norio M, Yuji K, Masao O (2008) Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review. Hepatol Int 2(1):17–30CrossRefPubMed
Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A (2015) Tumor markers for hepatocellular carcinoma: simple and significant predictors of outcome in patients with HCC. Liver Cancer 4(2):126–136CrossRefPubMedPubMedCentral
Wang L, Yao M, Dong Z, Zhang Y, Yao D (2014) Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring. Tumour Biol 35(1):9–20CrossRefPubMed
Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, Zou L (2005) Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int 4(4):544–549PubMed
Yao DF, Dong ZZ, Yao M (2007) Specific molecular markers in HCC. Hepatobiliary Pancreat Dis Int 6(3):15–22
Yao DF, Wu W, Yao M, Qiu LW, Wu XH, Su XQ et al (2006) Dynamic alteration of telomeraseexpression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol 12(31):4966–4972
Metadata
Title
Estimation of telomerase, AFP, and AFP-L3 levels in Sudanese patients with hepatocellular carcinoma and chronic liver diseases
Authors
Fayza A. Rahamtalla
Mohammed S. M. Abdalla
Salma B. M. Mudawi
Mohammed A. H. Kheir Elsid
Iman M. Shammat
Publication date
01-09-2018
Publisher
Springer London
Published in
Comparative Clinical Pathology / Issue 5/2018
Print ISSN: 1618-5641
Electronic ISSN: 1618-565X
DOI
https://doi.org/10.1007/s00580-018-2709-2

Other articles of this Issue 5/2018

Comparative Clinical Pathology 5/2018 Go to the issue

Original Article

Respiratory and GIT tract immune responses of broiler chickens following experimental infection with Newcastle disease’s virus

Original Article

Nephroprotective activity of Alyssum meniocoides Boiss aqueous extract on streptozotocin-induced diabetic nephrotoxicity in male mice

Original Article

Hepatoprotective and hematoprotective effects of Falcaria vulgaris aqueous extract against CCl4-induced hepatic injury in mice

Original Article

Retrospective evaluation of canine fractures in southern Nigeria

Original Article

Seroprevalence of peste des petits ruminants among unvaccinated small ruminants in Sokoto State, northwestern Nigeria

Original Article

Occult hepatitis B infection: a hidden factor of poor response to intervention treatment of hepatocellular carcinoma in chronic hepatitis C patients